Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells

Biological Chemistry

Volumn 384, Issue 2, 2003, Pages 257-266

  Bhatt, Ami S ^a   Takeuchi, Toshi ^a,d   Ylstra, Bauke ^a,e   Ginzinger, David ^b   Albertson, Donna ^b   Shuman, Marc A ^a   Craik, Charles S ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BAYER CORPORATION   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast; Cancer; MT SP1; Protease; Serine

Indexed keywords

MEMBRANE PROTEIN; MESSENGER RNA; RNA; SERINE PROTEINASE; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER THERAPY; CELL TRANSFORMATION; COLON CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDODERM; ENZYME SUBSTRATE; EXTRACELLULAR SPACE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NORTHERN BLOTTING; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA TRANSCRIPTION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL LINE, TRANSFORMED; EPITHELIAL CELLS; FEMALE; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERINE ENDOPEPTIDASES; TISSUE DISTRIBUTION; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0037298739     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2003.029     Document Type: Article

References (43)

1. Bell, W. R. (1996). The fibrinolytic system in neoplasia. Semin. Thromb. Hemost. 22, 459-478.
2. Bouchet-Bernet, C., Spyratos, F., Andrieu, C., Deytieux, S., Becette, V. and Oglobine, J. (1996). Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues. Breast Cancer Res. Treat. 41, 141-146.
3. Broet, P., Spyratos, F., Romain, S., Quillien, V., Daver, A., Ricolleau, G., Rallet, A., Toulas, C. and Asselain, B. (1999). Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study. Br. J. Cancer. 80, 536-545.
4. Cao, J., Zheng, S., Zheng, L., Cai, X., Zhang, Y., Geng, L. and Fang, Y. (2001). A novel serine protease SNC19 associated with human colorectal cancer. Chin. Med. J. (Engl). 114, 726-730.
5. de Witte, J. H., Foekens, J. A., Brunner, N., Heuvel, J. J., van Tienoven, T., Look, M. P., Klijn, J. G., Geurts-Moespot, A., Grebenchtchikov, N., Benraad, T. and Sweep, C. G. (2001). Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br. J. Cancer. 85, 85-92.
6. Del Vecchio, S., Stoppelli, M. P., Carriero, M. V., Fonti, R., Massa, O., Li, P. Y., Botti, G., Cerra, M., D'Aiuto, G., Esposito, G. et al. (1993). Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: comparison with urokinase levels. Cancer Res. 53, 3198-3206.
7. Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A. and Chinnaiyan, A. M. (2001). Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822-826.
8. Duffy, M. J. (1990). Plasminogen activators and cancer. Blood Coagul. Fibrinolysis 1, 681-687.
9. Enyedy, I. J., Lee, S. L., Kuo, A. H., Dickson, R. B., Lin, C. Y. and Wang, S. (2001). Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase. J. Med. Chem. 44, 1349-1355.
10. Foekens, J. A., Peters, H. A., Look, M. P., Portengen, H., Schmitt, M., Kramer, M. D., Brunner, N., Janicke, F., Meijer-van Gelder, M. E., Henzen-Logmans, S. C., van Putten, W. L. and Klijn, J. G. (2000). The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 60, 636-643.
11. Ginzinger, D. G., Godfrey, T. E., Nigro, J., Moore, D. H., 2nd, Suzuki, S., Pallavicini, M. G., Gray, J. W. and Jensen, R. H. (2000). Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res. 60, 5405-5409.
12. Guyton, D. P., Evans, D. M. and Sloan-Stakleff, K. D. (2000). Urokinase plasminogen activator receptor (uPAR): a potential indicator of invasion for in situ breast cancer. Breast J. 6, 130-136.
13. Hanahan, D. and Weinberg, R. A. (2000). The hallmarks of cancer. Cell 100, 57-70.
14. Harbeck, N., Kates, R. E. and Schmitt, M. (2002). Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J. Clin. Oncol. 20, 1000-1007.
15. Hooper, J. D., Clements, J. A., Quigley, J. P. and Antalis, T. M. (2001). Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes. J. Biol. Chem. 276, 857-860.
16. Jankun, J., Merrick, H. W. and Goldblatt, P. J. (1993). Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J. Cell Biochem. 53, 135-144.
17. Kim, M. G., Chen, C., Lyu, M. S., Cho, E. G., Park, D., Kozak, C. and Schwartz, R. H. (1999). Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics 49, 420-428.
18. Koblinski, J. E., Ahram, M. and Sloane, B. F. (2000). Unraveling the role of proteases in cancer. Clin. Chim. Acta 291, 113-135.
19. Kotzsch, M., Luther, T., Harbeck, N., Ockert, D., Lutz, V., Noack, F., Grossmann, D., Albrecht, S., Kramer, M. D., Lossnitzer, A., Grosser, M., Schmitt, M. and Magdolen, V. (2000). New ELISA for quantitation of human urokinase receptor (CD87) in cancer. Int. J. Oncol. 17, 827-834.
20. Lee, S. L., Dickson, R. B. and Lin, C. Y. (2000). Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 275, 36720-36725.
21. Lin, C. Y., Anders, J., Johnson, M. and Dickson, R. B. (1999a). Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J. Biol. Chem. 274, 18237-18242.
22. Lin, C. Y., Anders, J., Johnson, M., Sang, Q. A. and Dickson, R. B. (1999b). Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J. Biol. Chem. 274, 18231-18236.
23. List, K., Haudenschild, C. C., Szabo, R., Chen, W., Wahl, S. M., Swaim, W., Engelholm, L. H., Behrendt, N. and Bugge, T. H. (2002). Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 21, 3765-3779.
24. Look, M. P. and Foekens, J. A. (1999). Clinical relevance of the urokinase plasminogen activator system in breast cancer. APMIS 107, 150-159.
25. Look, M. P., van Putten, W. L., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S. et al. (2002). Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. 94, 116-128.
26. Mazar, A. P. (2001). The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anticancer Drugs 12, 387-400.
27. Monsky, W. L. and Chen, W. T. (1993). Proteases of cell adhesion proteins in cancer Semin. Cancer Biol. 4, 251-258.
28. Oberst, M., Anders, J., Xie, B., Singh, B., Ossandon, M., Johnson, M., Dickson, R. B. and Lin, C. Y. (2001). Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am. J. Pathol. 158, 1301-1311.
29. Oberst, M. D., Johnson, M. D., Dickson, R. B., Lin, C. Y., Singh, B., Stewart, M., Williams, A., al-Nafussi, A., Smyth, J. F., Gabra, H. and Sellar, G. C. (2002). Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin. Cancer Res. 8, 1101-1107.
30. Paoloni-Giacobino, A., Chen, H., Peitsch, M. C., Rossier, C. and Antonarakis, S. E. (1997). Cloning of the TMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3. Genomics 44, 309-320.
31. Pedersen, A. N., Christensen, I. J., Stephens, R. W., Briand, P., Mouridsen, H. T., Dano, K. and Brunner, N. (2000). The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. Cancer Res. 60, 6927-6934.
32. Raja, S., Luketich, J. D., Kelly, L. A., Ruff, D. W. and Godfrey, T.E. (2000). Increased sensitivity of one-tube, quantitative RTPCR. Biotechniques 29, 702, 704, 706.
33. Riisbro, R., Christensen, I. J., Piironen, T., Greenall, M., Larsen, B., Stephens, R. W., Han, C., Hoyer-Hansen, G., Smith, K., Brunner, N. and Harris, A. L. (2002). Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin. Cancer Res. 8, 1132-1141.
34. Schneeberger, C., Speiser, P., Kury, F. and Zeillinger, R. (1995). Quantitative detection of reverse transcriptase-PCR products by means of a novel and sensitive DNA stain. PCR Methods Appl. 4, 234-238.
35. Sternlicht, M. D. and Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior. Annu. Rev. Cell Dev. Biol. 17, 463-516.
36. Takeuchi, T, Shuman, M. A. and Craik, C. S. (1999). Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc. Natl. Acad. Sci. USA 96, 11054-11061.
37. Takeuchi, T., Harris, J. L., Huang, W., Yan, K. W., Coughlin, S. R. and Craik, C. S. (2000). Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J. Biol. Chem. 275, 26333-26342.
38. Tanimoto, H., Yan, Y., Clarke, J., Korourian, S., Shigemasa, K., Parmley, T. H., Parham, G. P. and O'Brien, T. J. (1997). Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res. 57, 2884-2887.
39. Taylor, J. R. (1982). An Introduction to Error Analysis (Mill Valley, USA: University Science Books).
40. Tryggvason, K., Hoyhtya, M. and Salo, T. (1987). Proteolytic degradation of extracellular matrix in tumor invasion. Biochim. Biophys. Acta 907, 191-217.
41. Underwood, L. J., Shigemasa, K., Tanimoto, H., Beard, J. B., Schneider, E. N., Wang, Y., Parmley, T. H. and O'Brien, T. J. (2000). Ovarian tumor cells express a novel multi-domain cell surface serine protease. Biochim. Biophys. Acta 1502, 337-350.
42. Wallrapp, C., Hahnel, S., Muller-Pillasch, F., Burghardt, B., Iwamura, T., Ruthenburger, M., Lerch, M. M., Adler, G. and Gress, T. M. (2000). A novel transmembrane serine protease (TM-PRSS3) overexpressed in pancreatic cancer. Cancer Res. 60, 2602-2606.
43. Zhang, Y., Cai, X., Schlegelberger, B. and Zheng, S. (1998). As signment1 of human putative tumor suppressor genes ST13 (alias SNC6) and ST14 (alias SNC19) to human chromosome bands 22q13 and 11q245 by in situ hybridization. Cytogenet. Cell Genet. 83, 56-57.